WHO Approves Distribution Of Dexamethasone For Coronavirus Treatment
WHO has approved the production and distribution of dexamethasone for coronavirus treatment.
The World Health Organization (WHO), has approved the massive production and distribution of dexamethasone as treatment for severe covid-19 cases.
“The next challenge is to increase production and rapidly and equitably distribute dexamethasone worldwide, focusing on where it is needed most,” WHO Director General, Tedros Adhanom, said on Monday, at the press briefing in Geneva.
Recall that WHO had last week, confirmed that the “steroid dexamethasone has life-saving potential for critically ill COVID-19 patients.”
Adhanom stressed that ever since the government of the United Kingdom came up with the scientific breakthrough, demands for it have surged
He also stated that the fact that there were many approved drug manufacturers, maked it easy for the drug to circulate.
“Fortunately, this is an inexpensive medicine and there are many dexamethasone manufacturers worldwide, who we are confident can accelerate production,” he said.
Meanwhile, he urged that the drug be distributed to countries that needed it most, not those that have the purchasing power.
“Guided by solidarity, countries must work together to ensure supplies are prioritized for countries where there are large numbers of critically ill patients, and that supplies remain available to treat other diseases for which it is needed.
“Transparency and constant monitoring will be key to ensuring needs dictate supplies, rather than means,”he added.
WHO DG also cautioned against drug counterfeits, adding that the quality of the drug must be verified before use.
Again, he maintained that the drug should not be administered to covid-19 patients with milder diseases.
“It is also important to check that suppliers can guarantee quality, as there is a high risk of substandard or falsified products entering the market.
“WHO emphasizes that dexamethasone should only be used for patients with severe or critical disease, under close clinical supervision.
“There is no evidence this drug works for patients with mild disease or as a preventative measure, and it could cause harm,” his statement further read.
"Now more than ever, all countries must make universal health coverage a priority.
— World Health Organization (WHO) (@WHO) June 22, 2020